BTIG Maintains Buy on Bright Minds Biosciences, Raises Price Target to $147

Benzinga · 6d ago
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and raises the price target from $72 to $147.